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Abstract
Objective: We estimated the incremental cost and impact on diagnosis and treatment uptake of national rollout of Xpert
MTB/RIF technology (Xpert) for the diagnosis of pulmonary TB above the cost of current guidelines for the years 2011 to
2016 in South Africa.
Methods: We parameterised a population-level decision model with data from national-level TB databases (n=199,511) and
implementation studies. The model follows cohorts of TB suspects from diagnosis to treatment under current diagnostic
guidelines or an algorithm that includes Xpert. Assumptions include the number of TB suspects, symptom prevalence of
5.5%, annual suspect growth rate of 10%, and 2010 public-sector salaries and drug and service delivery costs. Xpert test
costs are based on data from an in-country pilot evaluation and assumptions about when global volumes allowing cartridge
discounts will be reached.
Results: At full scale, Xpert will increase the number of TB cases diagnosed per year by 30%–37% and the number of MDR-
TB cases diagnosed by 69%–71%. It will diagnose 81% of patients after the first visit, compared to 46% currently. The cost of
TB diagnosis per suspect will increase by 55% to USD 60–61 and the cost of diagnosis and treatment per TB case treated by
8% to USD 797–873. The incremental capital cost of the Xpert scale-up will be USD 22 million and the incremental recurrent
cost USD 287–316 million over six years.
Conclusion: Xpert will increase both the number of TB cases diagnosed and treated and the cost of TB diagnosis. These
results do not include savings due to reduced transmission of TB as a result of earlier diagnosis and treatment initiation.
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Introduction
South Africa bears a large share of the global burden of HIV
and tuberculosis (TB) co-infection, with a TB prevalence of 795/
100,000 in 2010 [1]. Recent studies have shown that up to 70%
of TB suspects tested for HIV are HIV co-infected, with TB
being the most common cause of mortality in HIV infected
persons [2]. South Africa also has a high burden of multi-drug
resistant TB (MDR-TB), with more than 7,000 cases diagnosed
in 2010 [1].
Inthiscontext,conventionalTBdiagnostictechnologiesthathave
been used for decades, such as smear microscopy, are no longer
reliable, because 24% to 61% of HIV-positive tuberculosis patients
are smear-negative [3]. Significant hope for turning the tide of the
TB epidemic thus lies with the recent development of rapid
molecular assays. One of these, the GeneXpert System (Cepheid,
Sunnyvale, CA) usingthe cartridge-based Xpert MTB/RIF (Xpert)
assay,allowsforrapiddetectionofMycobacteriatuberculosis(MTB)and
a rapid screen for rifampicin (RIF) resistance [4,5]. Once a sputum
sample has been collected from a patient, results are available in
about 2hours, without the requirement ofhighly trainedlaboratory
personnel or additional biosafety measures [4].
In a multi-centre, prospective evaluation that included two
South African sites, Xpert was found to be highly specific (99.2%)
and highly sensitive (98.2% in smear-positive patients and 72.5%
in smear-negative, culture-positive patients) for MTB [4]. Similar
results have been obtained in other studies [2,5]. In December
2010 the World Health Organization strongly recommended the
use of Xpert, endorsing it as ‘‘the initial diagnostic test in
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most TB suspects in South Africa [6].
In March 2011, the South African National Department of
Health announced a rapid, nationwide scale up of access to Xpert,
to be achieved within a 2–3 year period. In conjunction with the
South African National Health Laboratory Service (NHLS), it
launched a pilot program that placed Xpert platforms in 25 smear
microscopy laboratories across the country, with throughputs
ranging from 16 to more than 400 tests per day and all instruments
interfacing electronically with the centralised laboratory informa-
tion system. By July 2011, over 50,000 samples had been
processed, with a 3.4% error rate [7]. Based on this successful
pilot, existing Xpert-enabled laboratories are now being upgraded
to allow complete migration from smear microscopy to Xpert for
TB diagnosis. Next, Xpert will be placed in all laboratories in nine
designated high case-load districts. Finally, Xpert instruments will
be placed at all other existing smear microscopy laboratories, fully
replacing smear microscopy for the diagnosis of pulmonary TB in
South Africa. Smear microscopy capacity for monitoring of TB
treatment however will remain in these laboratories.
To help determine the additional budgetary resources required
to procure and utilise Xpert as planned, while taking into account
savings from the reduction in smear microscopy, the NHLS asked
us to estimate the impact of Xpert scale-up on the number of TB
cases diagnosed and treated and the incremental cost of the scale-
up plan. Here we report the main results of our analysis, which
have since been used to guide South Africa’s national policy.
Methods
Sources of Data
For this study we developed a model representing the diagnostic
process starting with TB suspects, continuing to TB cases, and
ending with treatment. The number of TB cases and cost were
calculated quarterly for the financial years 2011 to 2016, covering
theperiodfromApril2011toMarch2017.Dataforthemodelcame
from a random sample of all patients entered into the national-level
NHLSTBspecimendatabasein2010(n=1,329,664)andarandom
sample of all patients entered into the national-level Electronic TB
Register in 2010 (ETR, n=286,741). Access to the two databases
had been granted by the management of the NHLS and of the TB
unit in the South African Department of Health, respectively. The
databases hadbeenanonymisedforouruseanddidnotcontainany
patient identifiers. We also used results of South African Xpert
implementationstudies[4,5]andotherliterature[8–11].Additional
inputs on the performance ofthe Xpert test (RIFresistance rateand
test failure rate) were based on NHLS data from the Xpert pilot
phase during March and April 2011. Information on loss rates in
suspects and baseline bacteriological coverage came from the
Quarterly TB Statistics 2010 collected by the NDoH [12].
Data from the NHLS Database
The national-level database of the National Health Laboratory
Service provided model assumptions on the proportion of suspects
who were smear microscopy-positive and those who were culture-
positive (by smear status). The NHLS database contains the results
of all laboratory tests done in the public sector in South Africa,
with multiple entries for the same patient linked using the patient’s
name, first line of address, and date of birth. We requested a subset
of the database containing information on tests for TB (smear
microscopy, TB culture, line-probe assay, and drug-susceptibility
testing) of all patients who had an entry during the 2010 calendar
year, as well as all TB test data on the same patients for 2004 to
2009. Due to the size of the original database we used a random
sample of 100,000 patients (7.5% of all patients) for our analysis,
representing all provinces and all types of clinical settings. Since
the analysis was restricted to the diagnosis of TB in ambulatory
care settings (and the South African guidelines prescribe a different
approach to diagnosing patients in inpatient settings), we limited
our analysis to the 83,977 subjects who contributed samples from
outpatient clinics.
For positivity rates we used the first smear and/or culture
performed in 2010 only. Since the database contained no
information on whether tests were done for diagnostic or for
treatment monitoring purposes, we deleted from the database
everyone with a first entry in 2009 in order not to capture the
treatment monitoring smears and cultures done during 2010 for
patients initiated on treatment in 2009.
Data from the Electronic TB Register
The Electronic TB Register (ETR) provided model assumptions
on the proportion of patients with positive, negative, and unknown
HIV status; the proportion of patients with a TB history; and
proportions of smear and culture positive tests stratified by HIV
and TB history status. The ETR is a register of all patients
diagnosed with TB who are notified and initiated on treatment at
the clinic level. The register starts at the clinic level as a book with
one entry per notified patient. Copies of patient-level demographic
and diagnostic information and treatment outcomes are sent to the
district TB office several times a month, where they are entered
into an electronic database. We downloaded information on all
patients registered during the 2010 calendar year from all 9
provinces except KwaZulu Natal, for which data had been
captured in a different format. We restricted our analysis to
patients who had not moved or been transferred into the
programme while already on treatment in order to avoid
double-counting patients, and to patients with pulmonary TB.
The remaining sample size was n=57,688.
The database contained information for all patients on whether
diagnosed cases were new cases or re-treatment cases and for some
patientsonHIVstatus.Weusedtheproportionofre-treatmentcases
outofallcasestoinformourassumptionoftheproportionofpatients
withTBhistory.Inordertocalculatetheproportionofpatientswith
a positive, negative or unknown HIV status we removed all patients
with missing HIV information from the analysis (n=32,951). For
the analysis of proportions of smear and culture positive tests
stratifiedbyHIVstatusweregardedpatientswithanunknownHIV
status(5.87%)asHIVpositive,assuggestedintheSouthAfricanTB
diagnostic guidelines [13]. Information on pre-treatment microsco-
py status was missing in 21.38% of patients.
Scenarios and Algorithms
The model follows quarterly cohorts of TB suspects through up
to three diagnostic visits under either a baseline scenario (current
guidelines) or an Xpert scenario, under which the Xpert
technology is scaled up either by the end of 2012 (accelerated
scale-up) or by the end of 2013 (gradual scale-up). Both scale-up
scenarios start from an Xpert coverage of 16% in June 2011,
representing the existing level of Xpert capacity after the pilot
phase. Patients with a positive Xpert MTB diagnosis are assumed
to be initiated on treatment according to their resistance status at
the same visit as they receive the positive result. Under both
scenarios, we count patients as diagnosed even if they fail to return
for the visit at which the positive result would be communicated to
them, though they would not be assumed to initiate treatment, and
we assume no loss to follow up after treatment initiation since no
data is available yet on whether and how loss to treatment would
differ between diagnostic scenarios. The diagnostic algorithms
Cost of GeneXpert MTB/RIF in South Africa
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Africa’s current and proposed new guidelines for TB diagnosis, are
illustrated in Figure 1 and the treatment options for diagnosed
patients in Figure 2.
Model Inputs and Assumptions
Table 1 lists the model assumptions and their sources and
Table 2 the cost inputs.
Number of suspects. Numbers of suspects (patients and/or
contacts of TB cases with a positive TB symptom screen) were
calculated using data on the general population aged 15 years and
above from the Actuarial Society of South Africa AIDS Model
[15] and an assumption of a prevalence of TB symptoms of 5.5%
based on the Provincial Quarterly TB Reports [12]. In the main
analysis, this percentage increases by 10% every year, in line with
the targets for South Africa’s ongoing Intensified Case Finding
campaign [16]. In sensitivity analysis we consider rates of 0% and
6.5%, a rate suggested by the WHO Stop-TB ‘‘Planning and
Budgeting for TB Control’’ model for South Africa [17]. The
smear positivity rate is set at 9.89% of suspects at baseline, based
on the 2010 NHLS TB database, and, together with the culture
positive rate of smear negatives, decreases in both the baseline and
Xpert scenarios as a function of the growth in suspects, allowing us
to model a stable epidemic. This rate of decrease is calculated as
P(ssz)yz1 ~ P(ssz)y  (1{gr)
where P(ss+) is the proportion of patients who are smear-positive, y
is the model year, and gr is the rate of growth in suspects (10%,
0%, or 6.5% according to growth scenario). (The same calculation
applies to the proportion of smear-negative patients who are
culture-positive).
The current bacteriological coverage rate (the proportion of
suspectswhohaveadocumentedsmearmicroscopyresult,basedon
Figure 1. Diagnostic algorithm under current guidelines (Baseline scenario) and proposed new guidelines (Xpert scenario). LPA
denotes line probe assay; DST, drug-susceptibility testing. Adult patients with suspected pulmonary MTB infection undergo a number of TB
diagnostics at each of up to three consecutive diagnostic visits. Under the Baseline scenario, diagnostics are differentiated by whether or not patient
have a history of TB treatment, and, for smear-negative patients, by HIV status. Under the Xpert algorithm, diagnostics are differentiated by HIV status
for patients with a negative Xpert result only. Under both algorithms patients with a positive culture undergo further testing by line probe assay and,
if this shows a resistance to RIF and/or INH, by drug-susceptibility testing for second line TB drugs. Under the Xpert scenario, patients with a positive
Xpert result and RIF resistance (MTB+/RIF+) undergo further sputum microscopy and culture +/2 LPA +/2 DST for confirmation of the MDR-TB result
and exclusion of XDR-TB. For smear microscopy, two sputa are collected; for an Xpert test, a single sputum is used. All tests are done on spot sputum
samples.
doi:10.1371/journal.pone.0036966.g001
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constant inthe baseline scenario butincreases to 100%in the Xpert
scenario to reflect a higher use of laboratory diagnosis as a result of
the faster turn-around and greater specificity achieved by Xpert.
Cost data. We calculated the cost of TB diagnosis and
treatment under the baseline and the Xpert scenarios from the
government perspective, including the cost of outpatient visits,
equipment, drugs, laboratory and radiological tests, infrastructure,
training, and overhead. We used expert opinion and public-sector
salary data to estimate the duration and cost of clinic visits, 2010
NHLS charges for all laboratory costs except the Xpert test,
public-sector radiology costs, and public-sector drug costs and
standard treatment algorithms for presumptive antibiotic treat-
ment. TB treatment drug costs (including for mono-resistant and
MDR-TB treatment) were calculated using August 2011 drug
tender costs and the current South African TB guidelines [13]. All
non-drug outpatient costs are based on previously reported
estimates [11], adjusted for inflation to 2011 ZAR and converted
to USD at 1 USD =7.94 ZAR [18]. We included only outpatient
treatment costs for MDR-TB since during the projection period a
new strategy that replaces inpatient with outpatient care for MDR-
TB patients is planned to be rolled out [19]. Costs are reported in
2011 USD and presented undiscounted and inclusive of value-
added tax (VAT).
The per-test cost of the Xpert technology was calculated in a
separately-reportedanalysis[20],basedonabottom-upcostanalysis
of the pilot phase, estimates of the number and type of instruments
required given diagnostic sample volumes at NHLS smear
microscopy labs, and assumptions about when global volumes
allowing discounts on the international price of Xpert MTB/RIF
cartridges will be reached and how much of that global test volume
willbebornebySouthAfrica.Instrumentcostswereannualisedover
anexpectedusefullifeofthemodulesoffouryears;whenvaryingthe
value to 3, 5 and 8 years, we found the cost per Xpert test to be
insensitivetothisassumption.Theseparately-reported analysis[20]
estimatedthatintheperiod2011to2013,theaveragecostperXpert
test performed will start at USD 33 and then decline to USD 25
between 2014 and 2016 when higher volumes and the resulting
globalvolumediscountsarereached.Moredetailonthecostpertest
can be found in Table 2.
Sensitivity analysis. Unless otherwise stated, all Xpert
scenario results reported reflect accelerated scale-up, 10% growth
in suspects, and South Africa procuring 50% of global Xpert test
volumes [21]. In sensitivity analysis we considered variation in five
parameters: a) 0% and 6.5% growth rate in suspects; b) South
Africa’s share of global volumes at 90%; c) an impact of full Xpert
coverage on smear positivity and culture positivity rates of suspects
as a result of a reduction in transmission, based on the results of a
previous model [22], d) South Africa accessing Xpert cartridges at
the volume-discounted price of USD 10.72 ahead of global test
volumes reaching 3.4 million in December 2011, and e) an
additional 4 months of inpatient care per patient for MDR-TB,
valued at the national average cost per inpatient-day equivalent of
$168.28.
The study was approved by the Human Research Ethics
Committee of the University of the Witwatersrand and the
Institutional Review Board of Boston University Medical Center.
Results
Number of Suspects
Table 3 reports the projected numbers of suspects and
patients diagnosed with TB under the baseline and accelerated
Xpert scenarios. As a result of the 10% increase in suspects or
Figure 2. Treatment algorithm by resistance status. R denotes rifampicin, H, isoniazid, Z, pyrazinamide, E, ethambutol, S, streptomycin, OFX,
ofloxacin, KM, kanamycin, ETO, ethionamide, PZA, pyrazinamide, TRD, terizidone. Patients diagnosed with pulmonary TB are initiated on TB treatment
according to their drug resistance status and, for the Baseline scenario, by their TB history. In the Xpert scenario, all patients without resistance are
treated as New cases; regimen 2 is no longer used.
doi:10.1371/journal.pone.0036966.g002
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Scenario Value Source
Baseline scenario
Proportions of TB suspects All TB history No TB history
With TB history 0.20 22 ETR 2010
HIV+ 0.56 0.54 0.57 ETR 2010
HIV 2 0.38 0.41 0.37 ETR 2010
HIV unknown 0.06 0.04 0.06 ETR 2010
Diagnostic status All TB history No TB history
Proportion TB suspects sputum smear +
a 0.06–0.10
b 22 NHLS 2010
Smear +,H I V + 2 0.06–0.10 0.06–0.10 NHLS 2010
c
Smear +,H I V 22 0.05–0.08 0.06–0.10 NHLS 2010
c
Proportion of TB suspects culture + 0.20 22 NHLS 2010
Culture +, smear + 1.00 22 NHLS 2010
c
Culture +, smear 2 0.08–0.13 22 NHLS 2010
c
Culture +, smear 2,H I V + 2 0.08–0.13 0.08–0.14 NHLS 2010
c
Culture +, smear 2,H I V 22 0.06–0.11 0.07–0.12 NHLS 2010
Proportion of TB suspects diagnosed clinically
d 0.01 22 Assumption
Resistance All
RIF mono-resistance rate 0.01 Matsoso 2010 [8]
INH mono-resistance rate 0.02 Matsoso 2010 [8]
RIF + INH resistance rate 0.09 Matsoso 2010 [8]
LPA sensitivity for RIF resistance 0.99 Parssons 2011 [9]
LPA sensitivity for INH resistance 0.88 Parssons 2011 [9]
Visit inputs All
Time between first and second visit 3–5 days NDoH guidelines [13]
Time between second and third visit 6 weeks Chihota 2010 [10]
Proportion cultures positive at second (third) visit 0.05 (0.95) Chihota 2010 [10]
Proportion of clinically diagnosed TB suspects diagnosed at
second (third) visit
0.5 (0.5) Assumption
Loss to follow up after first visit 0.135 QTBS 2010 [12]
Loss to follow up after second visit 0.2582 Boehme et al 2011 (CT cohort) [5]
Sample losses All
Sample loss per sputum sample 0.01 NHLS 2010
Proportion of cultures contaminated 0.1 NHLS 2010
Proportion of contaminated cultures repeated 0.87 Assumption
Xpert scenario
Diagnostic status All Smear+ Smear-
Sensitivity for positive culture result, 1st test 0.80 1.00 0.79 M. Nicols (unpublished data); Boehme et al
2011 (CT cohort) [5]
Specificity for negative culture result, 1st test 0.99 22
Failure rate, 1st test 0.03 22 NHLS Xpert data May 2011
Failure rate, 2nd test 0.03 22 Assumption
Proportion of TB suspects culture +
of Xpert MTB+/RIF+ pts 0.99 M. Nicols (unpublished data)
of Xpert MTB+/RIF inconclusive pts 0.87 M. Nicols (unpublished data)
of Xpert unsuccessful twice, smear negative pts 0.06–0.11 Assumption (same as baseline rate)
of Xpert MTB-, HIV+ pts 0.05 Boehme et al 2011 (CT cohort) [5]
Proportion of TB suspects diagnosed by antibiotic trial and/or
chest X-ray (Xpert MTB, HIV+)
0.01 Assumption (same as baseline rate for smear
negative patients)
Resistance
RIF resistance rate (mono-resistance and MDR) 0.07 NHLS Xpert data May 2011
Cost of GeneXpert MTB/RIF in South Africa
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Intensified Case Finding campaign [16], along with some
population growth, the number of suspects requiring TB
diagnosis increased in the model from 1.9 million per year to
3.2 million per year. Fifty-six percent of suspects were assumed
to be HIV positive, based on data from the Electronic TB
Register.
Number of Patients Diagnosed with TB
By 2013, the first year of full Xpert coverage, 30% more
patients were diagnosed in the Xpert scenario than in the baseline
scenario. This difference increased annually until 2016 due to the
decreasing prevalence of smear-positive TB that resulted from
intensified case-finding and the higher sensitivity of the Xpert
algorithm for smear-negative TB. In addition, the Xpert algorithm
led to a 69% increase in the number of patients diagnosed with
drug resistance. The proportion of diagnosed patients with or
without drug resistance who were initiated on treatment increased
from 75% to 81%.
Tests Used and Timing of Diagnosis
Under the baseline scenario 43% of patients were diagnosed by
smear microscopy, 51% by culture, and 6% clinically. This
breakdown changed dramatically under the Xpert scenario, in
which 85% were diagnosed by Xpert, 12% by culture, 3%
clinically, and only 0.05% by smear microscopy. Figures 3 and 4
show the distribution of diagnoses across visits. As can be seen,
under the baseline scenario, 44% of all patients were diagnosed by
their second clinic visit, three to five days after the first visit, and
another 39% by visit 3, six to seven weeks after the second visit
(Figure 3). At full Xpert coverage in 2013, 82% of patients were
diagnosed by visit 2, three to five days after their initial
presentation, and 91% by visit 3. The difference in timing of
diagnosis was even more pronounced for MDR-TB patients, with
0% of patients diagnosed by their second visit under the baseline
scenario and 82% under the Xpert scenario (Figure 4).
While Xpert can largely replace smear microscopy for TB
diagnosis, it cannot yet be used as a substitute for microscopy in
treatment monitoring, since a DNA-based molecular test such as
Xpert is unable to distinguish between live and dead mycobac-
teria. As a result, all patients diagnosed at their first Xpert test as
MTB+ have to undergo additional smear microscopy for the
purpose of obtaining a baseline for treatment monitoring. The
WHO recommendation for the use of Xpert, moreover, currently
only applies to sputum samples, and not to smears done from other
materials for the diagnosis of extrapulmonary TB. The need for
some smear microscopy capacity thus remains, though the number
of smear microscopy tests decreased by 61–67% at full Xpert
coverage. Similarly, the number of diagnostic cultures declined by
21–23%, and the number of line-probe assays by 44–55%. The
number of drug-susceptibility tests required, in contrast, increased
by 52–65% at full Xpert coverage.
Total Cost, Incremental Cost, and Cost Per Case
The incremental capital cost of introducing Xpert technology
(including instruments, additional laboratory building space,
security, and training) between 2011 and 2016 was estimated to
be USD 22 million. The incremental recurrent cost (including
cartridges, staff, transport, and quality assurance) over this time
period varied between USD 287 million (gradual scale-up) and
USD 316 million (accelerated scale-up). Capital cost did not differ
between scale-up scenarios, but recurrent cost for the gradual
scale-up scenario was lower in the first two years owing to the
smaller number of machines placed and overall lower testing
capacity. The resulting incremental cost for the Xpert roll-out per
year was between USD 30 million and USD 64 million
(accelerated scale-up) and between USD 20 million and USD 64
million per year (gradual scale-up).
Table 4 presents the resulting cost of the TB diagnostic
programme (including laboratory cost, clinic visits, and clinical
diagnosis) and of the diagnostic and outpatient treatment
programme combined. At full Xpert coverage (from 2013
onwards) the Xpert technology increased the total cost of the
TB diagnostic programme by between 53% and 57%, or USD 48
million to USD 70 million, per year. The cost per suspect tested
increased by USD 21 to USD 22 per year, or between 53% and
57%. The cost per patient diagnosed with TB increased by
between USD 46 and USD 52 per year, or 15% to 17%.
The outpatient cost of the TB treatment programme, assuming
full coverage with treatment, increased by USD 55–62 million per
year from 2013 onwards, or by 34–37%. This increase was the
result of a rise in the number of patients initiating treatment due to
lower loss to care during the diagnostic process. The cost of the full
TB diagnostic and treatment programme per patient diagnosed
and treated increased by USD 53–58 per year, or 7–8% (Table 4).
Table 1. Cont.
Scenario Value Source
Xpert RIF resistance sensitivity 0.90 Boehme et al 2011 (CT cohort) [5]
Xpert RIF inconclusive rate 0.02 NHLS Xpert data May 2011
Xpert RIF susceptible rate 0.91 Calculated from above
Visit inputs
Loss to follow-up after first visit 0.133 M. Nicols (unpublished data)
Loss to follow-up after second visit 0.26 Boehme et al 2011 (all cohorts) [5]
ETR 2010, Electronic TB Register 2010; NHLS 2010, National Health Laboratory Services database 2010; NDoH guidelines, South African National TB Guidelines [13]; QTBS
2010, Quarterly TB Statistics, National Department of Health 2010 [12].
aTwo sputa.
bThe proportion smear positive amongst all patients, and the proportion culture positive amongst smear negative patients, decreases in both scenarios over time as a
function of the growth in suspects, allowing us to model a stable epidemic.
cAdjusted using weights by HIV and history status from ETR.
dSmear negative, diagnosed by antibiotic trial and/or chest x-ray.
doi:10.1371/journal.pone.0036966.t001
Cost of GeneXpert MTB/RIF in South Africa
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36966Sensitivity analysis
In sensitivity analysis we found the annual diagnostic and
treatment cost to be sensitive to the assumption of growth in the
number of suspects (under full Xpert coverage, reduction in cost of
7.7% to 20% for 0% growth, and by 2.5% to 7.3% for 6.5%
growth) and to assumptions about an impact of full coverage with
Xpert technology on transmission via a reduction in the smear and
culture positivity rates in suspects (reduction in cost of 3.7% to
11.2%) (Table 4). Results were not sensitive to changes in the
assumption about South Africa’s share of the total Xpert test
volume from 50% to 90%. Including an approximation of
inpatient cost for MDR-TB, however, doubled the total cost of
the Xpert scale-up due to the large number of additional cases
of MDR-TB diagnosed by Xpert.
The accelerated scale-up scenario and an assumption of 50%
volume share led to price reductions being realised earlier and to
Table 2. Cost inputs in 2011 USD.
Cost item Cost Source
TB diagnosis
Baseline scenario
Sputum microscopy (fluorescent microscopy) 3 NHLS 2011 charges
TB culture (liquid medium, growth) 16 NHLS 2011 charges
TB culture (liquid medium, no growth) 12 NHLS 2011 charges
Line probe assay (LPA) for all positive cultures 24 NHLS 2011 charges
Drug susceptibility test (DST) (first-line drugs only) 72 NHLS 2011 charges, NHLS 2010 database
Chest x-ray 14 Public-sector charges
Antibiotic trial (amoxicillin and additional cotrimoxazole for PCP pneumonia
for all HIV+ patients)
2 Own data
Clinic visit: Nurse 9 Own data
Clinic visit: Physician 16 Own data
Xpert scenario
Instrument cost (desktop-computer model)
GX4 20,832 Cost analysis of NHLS pilot
GX8 54,077
GX12 70,541
GX16 86,919
GX48 394,657
Recurrent cost per test
Total per test 32
Cartridge (including shipping) 15–22
a
Staff 3
Overheads 3
Transport and logistics 2
Calibration 1
Training and quality assurance 0.5
Consumables 0.4
Waste disposal 0.3
Sample collection 0.3
TB treatment per course (regardless of diagnostic scenario)
First-line treatment (non- resistant) 429 Drugs: Government drug depot information and South African TB
Guidelines [13];
All other: Sinanovic et al 2003 [11]
Second-line treatment (non-resistant) 823
RIF monoresistance 3,280
INH monoresistance 796
Multi-drug resistance (outpatient care only) 3,280
Inpatient care for MDR-TB (sensitivity analysis only) 20,530
aIn an agreement between the manufacturer and the Foundation for Novel Diagnostics (FIND), the cost of Xpert cartridges for the public sector in 116 high-burden and
all low- and middle-income countries has been set to USD 16.86 apiece for volumes of between 600,000 to 1.7 million globally turned-over cartridges, USD 14.00
between for volumes between 1,700,001 to 3,700,000, and USD 10.72 for volumes from 3,700,001 cartridges onwards [14]. The cost used here includes the cost of
shipping to South Africa and local value-added tax.
doi:10.1371/journal.pone.0036966.t002
Cost of GeneXpert MTB/RIF in South Africa
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36966Table 3. Number of suspects and number of patients .15 years diagnosed with TB per year, by scenario.
2011 2012 2013 2014 2015 2016 TOTAL Avg. (% of total)
All scenarios
All suspects 1,883,591 2,091,621 2,320,890 2,573,504 2,851,790 3,158,305 14,879,701 2,479,950 (100%)
-H I V + 1,062,910 1,180,302 1,309,678 1,452,228 1,609,265 1,782,231 8,396,615 1,399,436 (56%)
-H I V 2 710,114 788,541 874,976 970,211 1,075,125 1,190,681 5,609,647 934,941 (38%)
- unknown HIV status
a 110,567 122,778 136,236 151,065 167,400 185,392 873,438 145,573 (6%)
-smear positive 182,440 182,331 182,085 181,713 181,227 180,635 1,055,719 175,953 (7%)
-smear negative 1,701,150 1,909,291 2,138,805 2,391,791 2,670,563 2,977,670 13,823,982 2,303,997 (93%)
Baseline scenario
Number of suspects diagnosed 335,930 339,433 342,709 345,814 348,801 351,724 2,064,411 344,068
% of suspects 18% 16% 15% 13% 12% 11% 14% 14%
Number of patients with drug
susceptible TB
316,646 319,354 322,474 325,454 328,347 331,205 1,943,480 323,913
Number of patients with drug
resistant TB
b
19,284 20,078 20,236 20,360 20,453 20,519 120,930 20,155
% drug resistance
b 4% 4% 4% 4% 4% 4% 4% 4%
Xpert scenario (accelerated scale-up, 10% growth in suspects)
Number of suspects diagnosed 369,054 412,133 446,985 457,852 469,357 481,633 2,637,013 439,502
% of suspects 20% 20% 19% 18% 16% 15% 18% 18%
Number of patients with drug
susceptible TB
346,235 384,682 416,174 426,110 436,619 447,823 2,457,643 409,607
Number of patients with drug
resistant TB
b
22,819 27,450 30,811 31,742 32,738 33,809 179,370 29,895
% drug resistance
b 6% 7% 7% 7% 7% 7% 7% 7%
Change between Xpert and baseline scenarios
Incremental suspects diagnosed 33,124 72,700 104,275 112,039 120,556 129,908 572,603 95,434
% change 10% 21% 30% 32% 35% 37% 28% 28%
% change in patients with drug
susceptible TB
13% 28% 39% 41% 42% 44% 26% 26%
% change in patients with drug
resistant TB
b
27% 51% 69% 69% 70% 71% 48% 48%
aSuspects with unknown HIV status are assumed to be HIV positive, in keeping with the South African TB guidelines [15].
b‘‘Drug resistant TB’’ includes INH mono-resistance, RIF mono-resistance, and multi-drug resistance.
doi:10.1371/journal.pone.0036966.t003
Figure 3. Timing of diagnosis for all patients. Percentage of all patients diagnosed by visit 2 (assumed 5 days after first visit), by visit 3 (assumed
4–6 weeks after first visit), and thereafter (accelerated scale-up, 10% growth in suspects).
doi:10.1371/journal.pone.0036966.g003
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on 3.4 million accumulative cartridges sold ahead of time, i.e., in
December 2011, saves 26% of total diagnostic and treatment cost
over the first 3 years.
Discussion
Based on the model we developed for the South African
National Department of Health, we estimate that the introduction
of Xpert technology will substantially increase the number of TB
cases diagnosed, MDR-TB cases identified, and patients started on
appropriate treatment. It will also accelerate diagnosis, with 82%
instead of 44% of patients diagnosed after the first visit. While
these results are clear improvements in the performance of the TB
diagnostic programme, they come at a cost, with the annual cost of
the diagnostic programme increasing by 53–57% annually at full
Xpert coverage, or USD 48–70 million per year, and the annual
cost of the treatment programme increasing by 34–37%. The
projected total cost of TB diagnosis and treatment in 2011 under
the accelerated Xpert scenario, USD 293 million, is 35% more
than the USD 218 million estimated as the total public-sector TB
budget for 2011 [1], although it comprises only 2% of the total
public health budget of South Africa for that year [23]. Potential
cost savings could come from the country’s guaranteeing to
procure certain test volumes in order to access volume-dependent
cartridge price discounts ahead of time, simultaneously ensuring
access to Xpert technology at the lower price for all other
countries.
The prospect of new molecular technology for the diagnosis of
TB and MDR-TB with a potential for implementation at point of
care gave rise to a number of papers urging that the operational
difficulties of using this technology be taken into account alongside
the standard cost and effectiveness considerations [22,24–26].
Although it is impossible to foresee all the challenges that large-
scale implementation of Xpert will generate, we attempted to
incorporate these concerns into our model by capturing impacts
and costs for up to three consecutive visits per patient and
including patient and sample loss rates and test failure rates at
every step. We also attempted to reduce bias introduced by trial-
specific cost and selection by basing most epidemiological
parameters on national-level operational data, rather than clinical
trial results.
The analysis presented here is limited in several ways. First, our
epidemiological model inputs are based on national-level data-
bases which are designed for routine patient care and programme
monitoring. Although this allows us to use data from a far larger
patient sample than is available in clinical trials and observation
studies, mismatching by the linking mechanism in the NHLS
database or missing data in both databases could have introduced
bias into our analysis. Since the resulting parameter values are
similar to those reported by the national TB programme [1] we do
not believe this bias to be large. Second, our analysis is restricted to
the full and incremental cost of the new diagnostic algorithm only.
As such, it does not fully capture the potential benefits of the Xpert
technology, such as longer survival and better quality of life, or its
opportunity cost. Third, since the baseline scenario reflects current
guidelines for TB diagnosis, the frequency and cost of clinical
diagnosis and of treatment initiation without laboratory diagnosis
and the potential cost-saving if Xpert diagnosis prevents these
patients from being treated might be underestimated. Fourth, we
do not include loss to follow-up from treatment, which could be
higher in the Xpert scenario as patients who would previously
have been lost to follow-up during a longer diagnostic process
might now be lost during the early stages of TB treatment. Fifth, as
with any model of an intervention that has not yet been brought to
scale, our results assume that the impacts and costs seen in the
pilot phase of Xpert implementation in South Africa and in small
demonstration projects will continue to reflect the impacts and
costs when nationwide scale-up is achieved. While we have taken
some potential variation into account in our sensitivity analyses,
close monitoring of the scale-up will be needed to verify many of
the assumptions we have made. Sixth, the algorithm for Xpert
diagnosis might change in the years to come as a result of the
experience generated during the roll-out. Total diagnostic costs
may be reduced once greater confidence in the technology allows
for a less conservative algorithm for the management of HIV-
positive, Xpert negative patients to be implemented, or as a result
of increasing test volumes if Xpert becomes the diagnostic of
choice for paediatric TB suspects and suspects with extrapulmo-
nary TB as well. Finally, the role of MDR-TB treatment in driving
the total cost of the South African TB program is only partly
explored in the model. Our results indicate that costs would nearly
double if the existing inpatient model of MDR-TB treatment is not
Figure 4. Timing of diagnosis for patients with drug resistant TB. Percentage of patients with drug-resistant TB diagnosed by visit 2
(assumed 5 days after first visit), by visit 3 (assumed 4–6 weeks after first visit), and thereafter (accelerated scale-up, 10% growth in suspects).
doi:10.1371/journal.pone.0036966.g004
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2011 2012 2013 2014 2015 2016
Diagnostic cost only (Accelerated scale-up, 10% growth in suspects, South Africa at 50% share of global volume)
Annual cost
Baseline scenario 74,094,947 81,908,809 90,497,431 99,950,392 110,355,101 121,807,536
Xpert scenario 115,149,393 131,577,329 138,644,077 154,645,352 172,283,949 191,721,257
Incremental annual cost 41,054,446 49,668,521 48,146,647 54,694,959 61,928,848 69,913,721
% change 55% 61% 53% 55% 56% 57%
Cost per suspect
Baseline scenario 39 39 39 39 39 39
X p e r t s c e n a r i o 6 1 6 36 06 06 0 6 1
Incremental cost per suspect 22 24 21 21 22 22
% change 55% 61% 53% 55% 56% 57%
Cost per case diagnosed
Baseline scenario 221 241 264 289 316 346
Xpert scenario 312 319 310 338 367 398
Incremental cost per case 91 78 46 49 51 52
% change 41% 32% 17% 17% 16% 15%
Diagnostic and treatment cost (Accelerated scale-up, 10% growth in suspects, South Africa at 50% share of global volume)
Annual cost
Baseline scenario 233,518,340 243,301,039 253,275,412 264,001,919 275,592,346 288,166,684
Xpert scenario 293,359,370 332,505,982 356,333,459 375,834,175 397,077,794 420,274,541
Incremental annual cost 59,841,031 89,204,943 103,058,047 111,832,256 121,485,448 132,107,857
% change 26% 37% 41% 42% 44% 46%
Cost per suspect
Incremental annual cost due to MDR-TB 16,493,378 33,699,639 45,950,789 46,937,184 48,032,498 49,259,932
Baseline scenario 124 116 109 103 97 91
Xpert scenario 156 159 154 146 139 133
Incremental cost per suspect 32 43 44 43 43 42
% change 26% 37% 41% 42% 44% 46%
Cost per case diagnosed and treated
Baseline scenario 695 717 739 763 790 819
Xpert scenario 795 807 797 821 846 873
Incremental cost per case 100 90 58 57 56 53
% change 14% 13% 8% 8% 7% 7%
Sensitivity analysis
Diagnostic and treatment cost
Comparator:
Annual cost of Xpert scenario, accelerated scale-up, 10%
growth in suspects, South Africa at 50% share of global
volume, no impact on transmission under Xpert
293,359,370 332,505,982 356,333,459 375,834,175 397,077,794 420,274,541
Annual cost, 0% growth in suspects 292,161,355 319,454,961 329,074,987 331,720,629 334,173,849 336,446,725
% change 20.4% 23.9% 27.7% 211.7% 215.8% 220.0%
Annual cost, 6.5% growth in suspects 292,981,587 328,709,898 347,619,719 361,018,125 375,040,777 389,746,053
% change 20.1% 21.1% 22.5% 23.9% 25.6% 27.3%
Annual cost, SA’s share of global volume 90% 294,321,907 336,618,783 358,375,806 378,098,820 399,587,327 423,053,804
% change 0.3% 1.2% 0.6% 0.6% 0.6% 0.7%
Annual cost, assume impact on TB transmission and
reduction of smear and culture positive rate under Xpert
293,359,370 332,505,982 343,222,009 347,974,800 358,497,984 373,431,446
% change 0% 0% 23.7% 27.4% 29.7% 211.2%
Annual cost, access to cartridge price @ 3.4 million tests by
December 2011
283,221,432 282,951,630 329,113,173 375,834,175 397,077,794 420,274,541
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approved but not yet widely implemented in South Africa.
Limitations notwithstanding, it is clear from our model that
nationwide scale-up of Xpert MTB/RIF technology in South
Africa will substantially increase the cost of the national TB
diagnosis and treatment programmes. It will also vastly increase
the number of TB cases diagnosed, MDR-TB cases identified, and
patients initiating TB treatment. The importance of this potential
benefit in helping to turn the tide against TB in South Africa has
been recognised in policy, with the Minister of Health committing
in May 2011 to roll Xpert MTB/RIF technology out ‘‘to every
district in the next six months and to every facility in the next 18
months’’ [27]. As new data are made available over the course of
the national scale-up, we will update the model presented here to
continue to guide implementation decisions.
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